Tianhong Li, MD; PhD

Associate Professor

  • 2101 Citations
  • 24 h-Index

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Tianhong Li is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 12 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Co-occurring alterations in the RAS–MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation-positive lung cancer

Rotow, J. K., Gui, P., Wu, W., Raymond, V. M., Lanman, R. B., Kaye, F. J., Peled, N., Fece de la Cruz, F., Nadres, B., Corcoran, R. B., Yeh, I., Bastian, B. C., Starostik, P., Newsom, K., Olivas, V. R., Wolff, A. M., Fraser, J. S., Collisson, E. A., McCoach, C. E., Ross Camidge, D. & 5 others, Pacheco, J., Bazhenova, L., Li, T., Bivona, T. G. & Blakely, C. M., Jan 15 2020, In : Clinical Cancer Research. 26, 2, p. 439-449 11 p.

Research output: Contribution to journalArticle

  • 8 Scopus citations

    Emerging EML4-ALK Variant 5 as a Concurrent Resistance Mechanism to Osimertinib in a Patient With EGFR E19del/T790M NSCLC

    Yan, Y., Jiang, G., Ma, W., Li, T. & Wang, L., 2020, (Accepted/In press) In : Clinical lung cancer.

    Research output: Contribution to journalArticle

    Open Access

    Translational Biomarkers and Rationale Strategies to Overcome Resistance to Immune Checkpoint Inhibitors in Solid Tumors

    Chen, J. A., Ma, W., Yuan, J. & Li, T., Jan 1 2020, In : Cancer treatment and research. 180, p. 251-279 29 p.

    Research output: Contribution to journalArticle